Factors of therapeutic imbalance of antivitamins K and their haemorrhagic consequences in elderly;Les facteurs de déséquilibre thérapeutique des antivitamines K et leurs conséquences hémorragiques en pratique gériatrique

Therapie

Volumn 63, Issue 5, 2008, Pages 393-401

  Chatap, Guy ^a   Giraud, Karine ^b   Delay, Virginie ^b   Cassereau, Catherine ^b   Bastuji Garin, Sylvie ^c   Vincent, Jean Pierre ^b   Cornu, Henri Pierre ^a  

^a Hopital Rene Muret Bigottini   (France)

^b Hôpitaux Universitaires Henri Mondor   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

Anticoagulant; Elderly; Hemorrhage; INR; Medicine

Indexed keywords

ACENOCOUMAROL; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; FLUINDIONE; LACTULOSE; OFLOXACIN; PARACETAMOL; TRAMADOL; WARFARIN;

ACUTE DIARRHEA; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CASE CONTROL STUDY; CONTROLLED STUDY; DEHYDRATION; FEMALE; FEVER; GERIATRIC HOSPITAL; GERIATRICS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MEDICINE; PRIORITY JOURNAL;

EID: 58849166139     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2008058     Document Type: Article

References (49)

1. Siguret V, Pautas E, Le Blanche AF, et al. Anticoagulation orale par les AVK chez le patient très âgé. Sang, Thrombose et Vaisseaux 2004; Hors-série
2. Drouet L, Fiesssinger JN, Boneu B, et al. Mobilisation pour les antivitamines K. Sang, Thrombose et Vaisseaux 2000; 12: 347-9
3. Legrain S. Consommation médicamenteuse chez le sujet âgé. Consommation, prescription, iatrogénie et observance. http://www.has-sante.fr/portail/upload/docs/application/pdf/pmsa-synth-biblio- 2006-08-28-16-44-51-580.pdf
4. Copland M, Walker ID, Tait RC. Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med 2001; 161: 2125-8
5. Hart RG, Pearce LA, Agular MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67
6. nd edn. Oxford: Radcliffe Medical Press 2004: 141-244
7. Hylek EM, D'Antonio J, Evans-Molina C, et al. Translating the results of randomized trials into clinical practice. The challenge of warfarine candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006; 37: 1075-80
8. Chatap G, Giraud K, Vincent JP. Atrial fibrillation in the elderly: facts and management. Drugs & Aging 2002; 19: 819-46
9. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-96
10. Mant J, Hobbs R, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet 2007; 370: 493-503
11. Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin: the National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 124: 970-9
12. Torn M, Ward LE, Bollen M, et al. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005; 165: 1527-32
13. Kerin NZ, Blevins RD, Goldman L, et al. The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch Intern Med 1988; 148: 1779-81
14. Siguret V, Esquirol C, Debray M, et al. Surdosages en antivitamine K dans une population de patients hospitalisés âgés de plus de 70 ans. Presse Med 2003; 32: 972-7
15. Naganuma M, Shiga T, Nishikata K, et al. Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy. J Cardiovasc Pharmacol Ther 2001; 6: 363-7
16. Kurnik D, Loebstein R, Farfel Z, et al. Complex drug-drug disease interactions between amiodarone, warfarine, and the thyroid gland. Medicine 2004; 82: 107-13
17. Analyse des ventes de médicaments en France aux officines et aux hôpitaux 1991-2001. Document Afssaps. Août 2003 http://afssaps. sante.fr/pdf/5/ventmed1.pdf
18. Pitruzzella R, Franck J. Médications en institutions pour personnes âgées (Région Wallonne). La Revue de Gériatrie 2005; 30: 13-22
19. Antlitz AM, Mead JA, Tolentino MA. Potentiation of oral anticoagulant therapy by acetaminophen. Curr Ther Res Clin Exp 1968; 10: 501-7
20. Wittkowsky AK, Boccuzzi SJ, Wogen J, et al. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy 2004; 24: 1668-74
21. Gebauer MG, Nyford-Hansen K, Henschke PJ, et al. Warfarin and acetaminophen interaction. Pharmacotherapy 2003; 23: 109-12
22. Whyte IM, Buckley NA, Reith DM, et al. Acetaminophen causes an increased International Normalized Ratio by reducing functional factor VII. Therapeutic Drug Monitoring 2000; 22: 742-48
23. Fattinger K, Frisullo R, Masche U, et al. No clinically relevant drug interaction between paracetamol and phenprocoumon based on a pharmacoepidemiological cohort study in medical inpatients. Eur J Clin Pharmacol 2002; 57: 863-7
24. Gadisseur AP, Van Den Meer FJ, Rosendaal FR. Sustained intake of paracetamol (acetaminophen) during oral anticoagulant therapy with coumarins does not cause clinically important INR changes: a randomized double-blind clinical trial. J Thromb Haemost 2003; 4: 714-7
25. Kwan D, Bartle WR, Walker SE. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999; 39: 68-75
26. Lehmann DE. Enzymatic shunting: resolving the acetaminophen-warfarin controversy. Pharmacotherapy 2000; 20: 1464-8
27. Thijssen HH, Soute BA, Vervoort LM, et al. Paracetamol (acetaminophen) warfarin interactions: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamine K cycle. Thromb Haemost 2004; 92: 797-802
28. Sabbe JR, Sims PJ, Sims MH. Tramadol-warfarin interaction. Pharmacotherapy 1998; 18: 871-3
29. Scher M, Huntington N, Vitillo JA. Potential interaction between tramadol and warfarin. Ann Pharmacother 1997; 37: 646-7
30. Boeijinga JK, Van Meegen E, Van Den Ende R, et al. Lack of interaction between tramadol and coumarins. J Clin Pharmacol 1998; 38: 966-70
31. Hedenmalm K, Lindh JD, Säwe J. Increased liability of tramadol-warfarin interaction in individuals with mutations in the cytochrome P450 2D6 gene. Eur J Clin Pharmacol 2004; 60: 369-72
32. Chiffoleau A, Veyrac G, Dudouet D, et al. Tramadol et anticoagulants oraux : interaction ou facteurs confondants ? Therapie 2003; 58: 471-74
33. Vadlamudi RS, Smalligan RD, Ismail HM. Interaction between warfarin and levofloxacin: case series. South Med J 2007; 100: 720-4
34. Jones CB, Fugate SE. Levofloxacin and warfarin interaction. Ann Pharmacother 2002; 36: 1554-7
35. Gheno G, Cinetto L. Levofloxacin-warfarin interaction. Eur J Clin Pharmacol 2001; 57: 427
36. Ellis RJ, Mayo MS, Bodensteiner DM. Ciprofoloxacin-warfarin coagulopathy: a case series. Am J Hematol 2000; 63: 28-31
37. Washington C, Hou SY, Hughues NC, et al. Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics. J Clin Pharmacol 2007; 47(10): 1320-6
38. Visser LE, Van-Beest P, Wilson HP, et al. Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon. Br J Clin Pharmacol 2003; 57: 522-4
39. Vince B, Zeegen R, Drinkwater JE, et al. The effect of lactulose on the faecal flora of patients with hepatic encephalopathy. J Med Microbiol 1974; 7: 163-8
40. Demirkan K, Stephens MA, Newman KP, et al. Response to warfarin and oral anticoagulants: effects of disease states. South Med J 2000; 93: 448-54
41. Richards RK. Influence of fever upon the action of 4-hydroxy-coumarin (dicumarol). Science 1943; 97: 313
42. Loeliger EA, Van Der Esch B, Mattern MJ, et al. The biological disappearance rate of prothrombin, factors VII, IX, and X from plasma in hypothyroidism, hyperthyroidism, and during fever. Thromb Diath Haemorrh 1964; 10: 267-77
43. Oester YT, Keresztes-Nagy S, Mais RF, et al. Effect of temperature on binding of warfarine by human serum albumin. J Pharm Sci 1976; 65: 1673-7
44. Chow WH, Chow TC, Tse TM, et al. Anticoagulation instability with life-threatening complication after dietary modification. Postgrad Med J 1990; 66: 855-7
45. Kumik D, Lubetsky A, Loebstein R, et al. Multivitamin supplements may affect warfarin anticoagulation in susceptible patients. Ann Pharmacother 2003; 37: 1603-6
46. Khan T, Wynne H, Wood P, et al. Dietary vitamin K influence intra-individual variability in anticoagulant response to warfarin. Br J Haematol 2004; 124: 348-54
47. Beatty SJ, Mehta BH, Rodis JL. Decreased warfarin effect after initiation of high-protein, low-carbohydrate diets. Ann Pharmacother 2005; 39: 744-7
48. Smith JK, Aljazairi A, Fuller S. INR elevation associated with diarrhea in patient receiving warfarin. Ann Pharmacother 1999; 33: 301-4
49. Black JA. Diarrhea, vitamin K, and warfarin. Lancet 1994; 344: 1373 [Letter]